S C Broome, T Pham, A J Braakhuis, R Narang, H W Wang, A J R Hickey, C J Mitchell, T L Merry
Journal: Redox biology 2022;53():102341
PMID: 35623315
Exercise-induced stressors trigger an acute and transient upregulation of gene expression in skeletal muscle that, if reinforced by repeated exercise bouts as part of an exercise training program, results in phenotypic adaptations that improve skeletal muscle function. The aim of this study was to investigate the effect of mitochondria-targeted coenzyme Q10 (mitoquidone; MitoQ) supplementation on a) skeletal muscle mitochondrial and antioxidant gene transcriptional response to acute high-intensity exercise and b) skeletal muscle mitochondrial content and function following exercise training. This study is a double-blind, placebo-controlled parallel design study. Participants were randomised to receive MitoQ or an identical placebo. Participants were instructed to consume one tablet per day 30 min before breakfast for 10 days before the acute exercise trial until completion of the final study visit. Results show that the acute exercise-induced transcriptional response and training-induced mitochondrial adaptations in skeletal muscle are not attenuated by MitoQ supplementation. Furthermore, MitoQ enhances the effect of exercise training on peak power achieved during a ramp-incremental exercise test. Authors conclude that training-induced increases in peak power are enhanced following MitoQ supplementation. However, these effects do not appear to be related to an effect of MitoQ supplementation on exercise-induced oxidative stress or training-induced mitochondrial biogenesis in skeletal muscle.
The role of mitochondrial ROS in signalling muscle adaptations to exercise training has not been explored in detail. We investigated the effect of supplementation with the mitochondria-targeted antioxidant MitoQ on a) the skeletal muscle mitochondrial and antioxidant gene transcriptional response to acute high-intensity exercise and b) skeletal muscle mitochondrial content and function following exercise training. In a randomised, double-blind, placebo-controlled, parallel design study, 23 untrained men (age: 44 ± 7 years, VO: 39.6 ± 7.9 ml/kg/min) were randomised to receive either MitoQ (20 mg/d) or a placebo for 10 days before completing a bout of high-intensity interval exercise (cycle ergometer, 10 × 60 s at VO workload with 75 s rest). Blood samples and vastus lateralis muscle biopsies were collected before exercise and immediately and 3 h after exercise. Participants then completed high-intensity interval training (HIIT; 3 sessions per week for 3 weeks) and another blood sample and muscle biopsy were collected. There was no effect of acute exercise or MitoQ on systemic (plasma protein carbonyls and reduced glutathione) or skeletal muscle (mtDNA damage and 4-HNE) oxidative stress biomarkers. Acute exercise-induced increases in skeletal muscle peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α) mRNA expression were augmented in the MitoQ group. Despite this, training-induced increases in skeletal muscle mitochondrial content were similar between groups. HIIT-induced increases in VO and 20 km time trial performance were also similar between groups while training-induced increases in peak power achieved during the VO test were augmented in the MitoQ group. These data suggest that training-induced increases in peak power are enhanced following MitoQ supplementation, which may be related to the augmentation of skeletal muscle PGC1α expression following acute exercise. However, these effects do not appear to be related to an effect of MitoQ supplementation on exercise-induced oxidative stress or training-induced mitochondrial biogenesis in skeletal muscle.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.